Investigation Overview
San Diego, Jan. 07, 2012 (Shareholders Foundation) -- The announcement by Inhibitex, Inc. that it agreed to be acquired by Bristol-Myers Squibb for $26.00 per NASDAQ:INHX share prompted an investigation for investors in Inhibitex (INHX) shares concerning whether the offer to acquire Inhibitex and the buyout process are unfair to investors in NASDAQ: INHX shares and whether certain off...
You must register (for free) or login to view the entire investigation.